Balchem Corp.
- BCPC · Nasdaq
- Chemicals & Allied Products
- Montvale, NJ
- 1,352 employees
- CIK 0000009326
Updated from SEC filings through
Top things to know
Executives
- Ted Harris Chairman, President and CEO of Balchem 8-K, 2026-10-23
- Theodore L. Harris Chairman, President and Chief Executive Officer 10-K, 2026-02-20
-
C. Martin Bengtsson Executive Vice President and Chief Financial Officer 10-K, 2026-02-20 - Carl Martin Bengtsson EVP & Chief Financial Officer 4, 2026-02-13
- Ren Anthony Gonzalez SVP and Chief R&D Officer 3, 2026-09-24
- Erin Leigh Gilson Chief Accounting Officer 3, 2026-04-07
What leadership is saying
“Balchem delivered another excellent quarter, with healthy growth across all three of our reporting segments and record consolidated quarterly net sales, net earnings, and adjusted EBITDA”
Earnings press release (8-K Ex. 99.1), filed October 23, 2026
Balchem Corp is a U.S. public company in chemicals & allied products (SIC 2800), headquartered in Montvale, NJ. It trades as BCPC on Nasdaq. Revenue was $1.0B in the fiscal year ending December 31, 2025, +8.8% from the year before. It reported about 1,352 employees. Ted Harris is Chairman, President and CEO of Balchem.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.0B 10-K, 2026-02-20 | $954M 10-K, 2026-02-20 | $922M 10-K, 2026-02-20 | $942M 10-K, 2025-02-21 | $799M 10-K, 2022-02-24 |
| Operating income | $209M 10-K, 2026-02-20 | $183M 10-K, 2026-02-20 | $159M 10-K, 2026-02-20 | $145M 10-K, 2025-02-21 | $128M 10-K, 2024-02-16 |
| SG&A | $67.4M 10-K, 2026-02-20 | $67.6M 10-K, 2026-02-20 | $53.4M 10-K, 2026-02-20 | $55.7M 10-K, 2025-02-21 | $41.7M 10-K, 2024-02-16 |
| Net income | $155M 10-K, 2026-02-20 | $128M 10-K, 2026-02-20 | $109M 10-K, 2026-02-20 | $105M 10-K, 2025-02-21 | $96.1M 10-K, 2024-02-16 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Ted Harris | Chairman, President and CEO of Balchem | 8-K, 2026-10-23 |
| Theodore L. Harris | Chairman, President and Chief Executive Officer | 10-K, 2026-02-20 |
| C. Martin Bengtsson Group CFO & GM Animal Nutrition and Health at Balchem Corporation | Executive Vice President and Chief Financial Officer | 10-K, 2026-02-20 |
| Carl Martin Bengtsson | EVP & Chief Financial Officer | 4, 2026-02-13 |
| Ren Anthony Gonzalez | SVP and Chief R&D Officer | 3, 2026-09-24 |
| M. Brent Tignor CHRO at Balchem Corporation | Named in proxy bio: Senior Vice President and Chief Human Resources Officer | DEF 14A, 2026-04-27 |
| Erin Leigh Gilson | Chief Accounting Officer | 3, 2026-04-07 |
| George Graham Chief R&D Officer | Senior Vice President and Chief R&D Officer | 10-K, 2026-02-20 |
 Hatsuki Miyata EVP, General Counsel and Secretary at Balchem Corporation (ticker: BCPC), a global health and nutrients company; National Association of Corporate Directors (NA | Executive Vice President, Chief Legal Officer and Secretary | 10-K, 2026-02-20 |
 Martin L. Reid | Senior Vice President and Chief Supply Chain Officer | 10-K, 2026-02-20 |
 Frederic Boned President Human Nutrition & Health at Balchem | Senior Vice President and General Manager, Human Nutrition and Health | 10-K, 2026-02-20 |
| William A. Backus | Vice President and Chief Accounting Officer | 10-K, 2026-02-20 |
| Martin Luther Reid | SVP Chief Supply Chain Officer | 4, 2026-02-13 |
| Michael Brent Tignor | SVP & Chief HR Officer | 4, 2026-02-13 |
| Gunsteren Job Leonard van | SVP and GM, Specialty Products | 4, 2026-02-13 |
| Daniel Knutson | Board member (per proxy) bio: Class 3 Director | DEF 14A, 2026-04-27 |
What Balchem Corp does
Balchem Corporation (“Balchem,” the “Company,” “we” or “us”), was incorporated in the State of Maryland in 1967. We develop, manufacture, distribute and market specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, plant nutrition, sterilization, fumigation, and industrial markets.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 31.8 million (as of October 15, 2026) | 10-Q, October 23, 2026 |
|---|---|---|
| Public float | $5.1B (as of June 30, 2025) | 10-K, February 20, 2026 |
| Reportable segments | 3 (period ending September 30, 2026) | 10-Q, October 23, 2026 |
| Latest proxy statement | Meeting June 18, 2026 (filed April 27, 2026) | DEF 14A, April 27, 2026 |
| Auditor | Rsm Us LLP (New York, New York) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| December 4, 2025 | Gunsteren Job Leonard van SVP and GM, Specialty Products | Sale | 6,000 | $920K | Form 4, December 5, 2025 |
| December 3, 2025 | David B. Fischer Director | Sale | 8,000 | $1.2M | Form 4, December 5, 2025 |
| November 11, 2025 | Martin Luther Reid SVP Chief Supply Chain Officer | Sale | 1,200 | $185K | Form 4, November 13, 2025 |
Recent 8-K events
- 8-K filed 2026-10-23
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-31
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-27
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- 8-K filed 2026-06-22
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-04-30
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-02-20
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-02-19
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2025-12-10
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-10-21
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-07-31
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about Balchem Corp
- What does Balchem Corp do?
- In its own words, from Item 1 of its 10-K: "Balchem Corporation (“Balchem,” the “Company,” “we” or “us”), was incorporated in the State of Maryland in 1967. We develop, manufacture, distribute and market specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, plant nutrition, sterilization, fumigation, and industrial markets."
- What is Balchem Corp's revenue?
- $1.0B for the fiscal year ending December 31, 2025, from its 10-K filed February 20, 2026.
- Is Balchem Corp profitable?
- Balchem Corp reported net income of $155M for the fiscal year ending December 31, 2025.
- How many employees does Balchem Corp have?
- About 1,352 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Balchem Corp?
- Ted Harris, Chairman, President and CEO of Balchem, as named in a 8-K filed October 23, 2026.
- Who is the CFO of Balchem Corp?
- C. Martin Bengtsson, Executive Vice President and Chief Financial Officer, as named in a 10-K filed February 20, 2026.
- Where is Balchem Corp headquartered?
- Montvale, NJ.
- What is Balchem Corp's stock ticker?
- BCPC on Nasdaq.
- What industry is Balchem Corp in?
- Chemicals & Allied Products, SIC code 2800.
- What is Balchem Corp's website?
- balchem.com.
- When does Balchem Corp report earnings next?
- January 23, 2027. Source: estimate_8k_pattern.
- Is Balchem Corp a public company?
- Yes. Balchem Corp files with the SEC under CIK 0000009326 and trades as BCPC.
- Who audits Balchem Corp?
- Rsm Us LLP, New York, New York, as named in its latest annual report (10-K).
- How many shares of Balchem Corp are outstanding?
- 31.8 million shares as of October 15, 2026, from its 10-Q filed October 23, 2026.
- What is Balchem Corp's public float?
- $5.1B as of June 30, 2025, as reported on the cover of its 10-K filed February 20, 2026.
- How many business segments does Balchem Corp report?
- 3 reportable segments for the period ending September 30, 2026, from its 10-Q filed October 23, 2026.
- When is Balchem Corp's annual shareholder meeting?
- June 18, 2026, per its proxy statement (DEF 14A) filed April 27, 2026.
- Have Balchem Corp insiders traded stock recently?
- Since November 11, 2025, officers and directors reported 3 open-market sales worth about $2.3M and 0 purchases on Forms 4 and 5. The most recent: Gunsteren Job Leonard van (SVP and GM, Specialty Products) sold 6,000 shares on December 4, 2025.